EQL Pharma AB (publ) (STO:EQL)

EQL Pharma AB Statistics

Total Valuation

EQL Pharma AB has a market cap or net worth of SEK 1.79 billion. The enterprise value is 2.19 billion.

Market Cap	1.79B
Enterprise Value	2.19B

Important Dates

The next estimated earnings date is Wednesday, November 5, 2025.

Earnings Date	Nov 5, 2025
Ex-Dividend Date	n/a

Share Statistics

EQL Pharma AB has 29.53 million shares outstanding. The number of shares has increased by 0.81% in one year.

Current Share Class	29.53M
Shares Outstanding	29.53M
Shares Change (YoY)	+0.81%
Shares Change (QoQ)	-2.78%
Owned by Insiders (%)	2.31%
Owned by Institutions (%)	11.12%
Float	21.74M

Valuation Ratios

The trailing PE ratio is 43.02 and the forward PE ratio is 29.47.

PE Ratio	43.02
Forward PE	29.47
PS Ratio	4.50
PB Ratio	7.76
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 26.29, with an EV/FCF ratio of -111.83.

EV / Earnings	51.44
EV / Sales	5.50
EV / EBITDA	26.29
EV / EBIT	30.14
EV / FCF	-111.83

Financial Position

The company has a current ratio of 1.89, with a Debt / Equity ratio of 1.96.

Current Ratio	1.89
Quick Ratio	0.99
Debt / Equity	1.96
Debt / EBITDA	5.43
Debt / FCF	-23.09
Interest Coverage	3.97

Financial Efficiency

Return on equity (ROE) is 20.31% and return on invested capital (ROIC) is 8.97%.

Return on Equity (ROE)	20.31%
Return on Assets (ROA)	7.54%
Return on Invested Capital (ROIC)	8.97%
Return on Capital Employed (ROCE)	12.07%
Revenue Per Employee	19.90M
Profits Per Employee	2.13M
Employee Count	21
Asset Turnover	0.66
Inventory Turnover	1.48

Taxes

In the past 12 months, EQL Pharma AB has paid 11.09 million in taxes.

Income Tax	11.09M
Effective Tax Rate	20.67%

Stock Price Statistics

The stock price has decreased by -10.74% in the last 52 weeks. The beta is 0.57, so EQL Pharma AB's price volatility has been lower than the market average.

Beta (5Y)	0.57
52-Week Price Change	-10.74%
50-Day Moving Average	71.12
200-Day Moving Average	79.86
Relative Strength Index (RSI)	42.68
Average Volume (20 Days)	34,570

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, EQL Pharma AB had revenue of SEK 397.94 million and earned 42.54 million in profits. Earnings per share was 1.41.

Revenue	397.94M
Gross Profit	165.13M
Operating Income	72.60M
Pretax Income	53.63M
Net Income	42.54M
EBITDA	81.44M
EBIT	72.60M
Earnings Per Share (EPS)	1.41

Balance Sheet

The company has 56.11 million in cash and 451.73 million in debt, giving a net cash position of -395.62 million or -13.40 per share.

Cash & Cash Equivalents	56.11M
Total Debt	451.73M
Net Cash	-395.62M
Net Cash Per Share	-13.40
Equity (Book Value)	230.87M
Book Value Per Share	7.94
Working Capital	174.84M

Cash Flow

In the last 12 months, operating cash flow was -8.09 million and capital expenditures -11.48 million, giving a free cash flow of -19.57 million.

Operating Cash Flow	-8.09M
Capital Expenditures	-11.48M
Free Cash Flow	-19.57M
FCF Per Share	-0.66

Margins

Gross margin is 41.49%, with operating and profit margins of 18.24% and 10.69%.

Gross Margin	41.49%
Operating Margin	18.24%
Pretax Margin	13.48%
Profit Margin	10.69%
EBITDA Margin	20.46%
EBIT Margin	18.24%
FCF Margin	n/a

Dividends & Yields

EQL Pharma AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.81%
Shareholder Yield	-0.81%
Earnings Yield	2.37%
FCF Yield	-1.09%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	3